(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr. - 2Cyber Monday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- 3I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- 4Katz, IDF: We assassinated IRGC intelligence chief Majid Khademi
- 5German mid-sized firms gloomy on outlook, survey finds
- Instructions to Pick the Right Senior Protection Plan.
- What is colostrum? And should you be taking it?
- Single women risk rape and exploitation in search for better life in Europe
- Giude to Best Web based Learning Stage
- High velocity Internet services for Metropolitan Regions
- UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- Which Kind of Pet Makes the Incomparable Buddy?
- 7 Well known Vacation spots In The US
- Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
